Wuxi Biologics (Cayman), Inc. is an investment holding company, which provides end-to-end solutions and services for biologics discovery, development, and manufacturing services and manufacturing of biologics products. The company is headquartered in Wuxi, Jiangsu and currently employs 12,552 full-time employees. The company went IPO on 2017-06-13. The firm mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The firm mainly conducts its business in the domestic and overseas markets.
02269.HK stock price ended at $40.44 on 星期一, after rising 1.10%
On the latest trading day Feb 16, 2026, the stock price of 02269.HK rose by 1.10%, climbing from $41.00 to $40.44. Throughout the session, the stock experienced a volatility of 2.50%, with prices fluctuating between a daily low of $40.00 and a high of $41.00. Alongside this price increase, trading volume also rose by 37.6M shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 501.0K shares were traded, amounting to a market value of approximately $166.9B.